Last reviewed · How we verify
Entecavir, Adefovir
Entecavir and Adefovir are nucleoside/nucleotide reverse transcriptase inhibitors that block hepatitis B virus replication by inhibiting the viral polymerase enzyme.
Entecavir and Adefovir are nucleoside/nucleotide reverse transcriptase inhibitors that block hepatitis B virus replication by inhibiting the viral polymerase enzyme. Used for Chronic hepatitis B infection, Hepatitis B e antigen (HBeAg)-positive chronic hepatitis B, Hepatitis B e antigen (HBeAg)-negative chronic hepatitis B.
At a glance
| Generic name | Entecavir, Adefovir |
|---|---|
| Sponsor | Nanfang Hospital, Southern Medical University |
| Drug class | Nucleoside/nucleotide reverse transcriptase inhibitor |
| Target | Hepatitis B virus polymerase (reverse transcriptase) |
| Modality | Small molecule |
| Therapeutic area | Virology/Hepatology |
| Phase | FDA-approved |
Mechanism of action
Both drugs are nucleoside analogues that are phosphorylated intracellularly and incorporated into the growing viral DNA chain, causing chain termination and preventing HBV replication. Entecavir is a guanosine analogue with higher potency and lower resistance rates, while Adefovir is an acyclic nucleotide analogue. They work by inhibiting the reverse transcriptase activity of the hepatitis B polymerase.
Approved indications
- Chronic hepatitis B infection
- Hepatitis B e antigen (HBeAg)-positive chronic hepatitis B
- Hepatitis B e antigen (HBeAg)-negative chronic hepatitis B
Common side effects
- Lactic acidosis
- Hepatomegaly
- Elevated transaminases
- Headache
- Fatigue
- Nephrotoxicity (Adefovir)
Key clinical trials
- Halting Nucleoside Analogues in Chronic Hepatitis B (NA)
- Carvedilol for Prevention of Esophageal Varices Progression (NA)
- Hepatitis B Virus (HBV) Viral Suppression by Entecavir in Adefovir Partial Responders
- Effects of Antiviral Therapy on Patients With HBV-related HCC
- Extension Study of Carvedilol RCT Study (NA)
- Safety, Tolerability and Antiviral Activity of Selgantolimod in Virally-Suppressed Participants With Chronic Hepatitis B (PHASE2)
- Real World Study About Anti-viral Regimen Adjustment on Achieving Complete Response in CHB Patients
- Improvement of Hard Endpoint in Chronic Hepatitis B Patients Treated With Antiviral Therapy
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Entecavir, Adefovir CI brief — competitive landscape report
- Entecavir, Adefovir updates RSS · CI watch RSS
- Nanfang Hospital, Southern Medical University portfolio CI